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ABSTRACT
Objective: The cure rate after treatment of bacterial vaginosis (BV) differs in various investigations,
but most studies report a cure rate of 70% after 1 month.
Methods: A long-term observation study after successful treatment ofBV has been undertaken.
The original study was a treatment study ofBV and included 50 patients.
Results: We were able to identif 44 of the original 50 patients. The mean follow-up time was 6.9
years (range 4.7-9 years). During this time, 21 women (48%) had been free ofBV while 23 women
had had relapses. There was no difference in the use of broad-spectrum antibiotics, episodes of
candida vaginitis, bleeding disturbances, family planning method, development of cervical intraep-
ithelial neoplasia (CIN), or gynecological operations between women with and without relapses.
The women with relapses had had a new sexual contact more often during the observation period
than women without relapses. There was no difference in hydrogen peroxide production of the
lactobacilli among women with or without relapses, and survival analysis shows that most relapses
occur during the first year after treatment.
Conclusions: If patients are successfully treated, half of the patients will stay cured indicating that
treatment is of benefit. Most relapses occur during the first year. Our results indicate that the
etiology ofBV might have something to do with new sexual contacts. Infect. Dis. Obstet. Gynecol.
5:297-302, 1997. (C) 1998 Wiley-Liss, Inc.
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he cure rates after treatment of bacterial vagi-
nosis (BV) differ in various studies. The drug
of choice has been metronidazole tablets 500 mg
BID for 7 days. The 1 week cure rate after start of
treatment is said to be about 90%, while evaluation
after month reveals a lower cure rate. In open
studies the month cure rate is 82%, while in blind
studies it is 65%. In the few published studies with
follow-up time of 3 months or more the cure rate
ranged from 25 to 77%. 2,3 No treatment studies
have been published with follow-up times longer
than 6 months.4
Several factors could influence the rate of recur-
rent BV: 1) inadequately treated infection, 2) the
patient’s local defense system, partly represented
by the HzOz-producing lactobacilli in the vagina, 3)
other vaginal infections, or 4) the consumption of
antibiotics. For sexually transmitted diseases
(STDs) the number of sexual partners is known to
affect the relapse rate, but it is still controversial
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whether BV should be regarded as an STD. Hart5
found BV to be associated with sexual activity but
not other STDs and among pregnant women there
is shown to be a coinfection between BV and other
STDs. 6 However, in epidemiological studies
among non-pregnant women, BV has not been
shown to be an STD,7,8 and partner treatment has
not been shown to be of any benefit in the cure
rate. z
The purpose of this study was to evaluate the
long-term cure rate after successful, treatment of
BV, to retrospectively register the number of re-
treatments of BV during the study period, and to




This study is based upon a previously performed
double blind, placebo controlled treatment study
of metronidazole 500 mg TID for 10 days.4 The
inclusion criteria for the initial study were fulfilling
three of four criteria for BV set by Amsel et al.9
(typical discharge, elevated pH, positive sniff test,
and presence of clue cells in wet smear). To this an
additional criterion was added: the motile rod-
shaped bacteria Mobiluncus should be seen by wet
smear microscopy.
In the primary study, 50 patients were enrolled.
All patients treated with placebo or those with
treatment failure after 1 month were retreated with
the same regimen of metronidazole tablets and
once again followed up month later until they
were cured. A 6 month follow-up after successful
treatment was performed. All further visits to our
outpatient clinic after the 6 month follow-up were
registered, and after about 5 years the patients
were contacted and offered a study visit at our out-
patient clinic. Women that had moved from our
area were traced through their security number.
The women had a personal interview and answered
a preformed questionnaire, were examined for BV,
and had a swab taken for culture of lactobacilli.
Women who were not able to come to our clinic
were sent a written instruction and a vaginal spec-
ulum to take a vaginal air-dried smear themselves
and to take a vaginal sample with a cotton swab
which was sent for culture. Smears that are ob-
tained blindly have been shown to be reliable for
the diagnosis of BV.1 The air-dried smears taken
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outside our clinic were sent to us by mail, thereby
making it possible for us to examine all of the
smears ourselves according to a previously de-
scribed method. 11
Microbiological Examination
Vaginal samples were collected by cotton swabs
and transported by mail in Stuart’s medium to the
laboratory. Cultures for lactobacilli were performed
anaerobically on Rogosa agar plates and blood agar
plates. Genus and species determinations of iso-
lated gram-positive, catalase-negative rods were
performed by biochemical methods (API-Coryne,
Merieux, France) and gas chromatography and
supplemented by DNA sequencing of the gene for
16S rRNA. Isolated strains were tested for hydro-
gen peroxide production by the method described
by Eschenbach et al. lz If more than one lactoba-
cillus strain was isolated, but only one was HzOz-
producing, we assumed that the woman had an
HzOz-producing strain of lactobacillus.
At the follow-up examination BV was diagnosed
according to the established criteria of Amsel et al.9
For the 4 patients with self-taken smears, the di-
agnosis was made solely by investigating the rehy-
drated air-dried smear. BV was then defined as
presence of clue cells, overgrowth of coccoid-like
bacteria, and lack of lactobacilli.1
Questionnaire
All of the women answered a preformed question-
naire where we asked about intercurrent diseases
since the initial study, surgery, pregnancies, family
planning methods, bleeding disturbances, new sex-
ual contacts, number of episodes of candida vagi-
nitis, and use of antibiotics during the follow-up
period.
Bleeding disturbances were defined as small in-
termenstrual bleeding episodes, spottings, or in-
creased menstrual bleedings. Information about
new sexual contacts was extracted from the ques-
tionnaire. Episodes of candida vaginitis were de-
fined as candidiasis diagnosed and treated by a
physician. During the study period it was not pos-
sible to buy anti-candida medications over the
counter in Sweden. Nearly all patients had used
some kind of antibiotics during the follow-up pe-
riod. In case the patient had been treated for in-
fections other than upper respiratory tract infec-
tions or lower urinary tract infections we presumed
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TABLE I. Number of relapses of BV during the
observation period
No. of No. of patients Cumulative number
relapses (n 44) of relapses
0 21 (48%) 0 (0%)
II (25%) II (48%)
2 7 (I 6%) 18 (78%)
3 4 (9%) 22 (96%)
4 (2%) 23 ( 00%)
that broad-spectrum antibiotics had been used.
Number of relapses of BV during the observation
period was recorded according to the patient’s
medical history, and both the diagnosis and treat-
ment regimen were verified through the patient’s
medical record. The population in our community
is rather stabile and there has not been any other
gynecological outpatient clinic in the town until
recently.
Statistics
We used chi-square as statistics and P < 0.05 was
defined as significant. The time from the initial
proven cure to the first relapse, as well as the time
from proven cure after the first relapse to the sec-
ond relapse, were used in a survival analysis model.
RESULTS
Of the original 50 patients, 6 women were not lo-
cated because of emigration or a failure to answer
our letter. The 44 remaining patients had a mean
follow-up time of 6.9 years (range 4.7-9 years) since
the successful completion of treatment for BV. Of
the 44 patients, 21 had had no symptoms or signs of
BV during the total study time. The other 23 pa-
tients had 1-4 diagnosed relapses of BV per patient
(mean incidence of 1.8 per patient) (Table 1).
The mean age did not differ between women
with (43.5 years) and without (43.8 years) relapse of
BV. Significantly more women with relapse of BV
reported new sexual contacts during the study pe-
riod (Table 2). No differences were seen during
the observation period among the two groups ac-
cording to use of contraception, episodes of can-
dida infections, treatment with broad-spectrum an-
tibiotics, bleeding disturbances, cervical intraepi-
thelial neoplasia (CIN), or gynecological diseases
requiring operative intervention.
The time between initial proven cure and the
first relapse is shown in Figure using a survival
analysis model. The first curve is based on 43 pa-
tients with 56 months of follow-up. One woman is
not included in the survival curve as we were not
able to identify the date of the first relapse. The
second curve is based on 31 patients with 72
months of follow-up. Most of the women (16/22,
73%) relapsed during the first year after the initial
treatment. We divided the relapses into early and
late relapses (relapse within or after the first year of
effective treatment). Five of 6 women (83%) with a
late relapse of BV had a new sexual contact, com-
pared to 63% (10/16) of the women with an early
relapse (P 0.70).
Six of 8 women who in the initial study needed
a repeated metronidazole treatment for cure of BV
had a new relapse of BV during the 6 years obser-
vation. Most of these relapses occurred as an early
relapse (5/6).
We were able to culture Lactobacillus spp. from
22 of the 41 women with lactobacillus morphotype
in the wet smear. Of these, 3 strains died before
testing for HzOz production. There was no differ-
ence in the isolation of HeOe-producing strains of
lactobacilli among women with and without re-
lapse. HeOz production was present in 4 of 9 (44%)
lactobacilli strains in the relapse group and 4 of 10
(40%) in the group who remained free of disease.
In most cases, the lactobacilli were phenotypically
classified into Lactobacillus spp. and no particular
strain was correlated to women with relapse of BV.
The genotypic classification showed that most
strains were L. acidophi/us and L. plantarum, and no
difference between the women with and without
relapses was found.
DISCUSSION
The recurrence of BV after treatment may be
high.
3 This has been used as an argument not to
recommend the treatment of BV among asymp-
tomatic women. Our results indicate that approxi-
mately half of the patients will remain free of BV
for up to 5 years after initial successful treatment,
indicating a benefit of treating women with BV.
BV is microbiologically characterized by a deple-
tion of lactobacilli and overgrowth of G. vaginalis
and anaerobes. The use of antibiotics could theo-
retically facilitate a bacterial shift toward a BV as-
sociated flora. In our study, all but two of the pa-
tients had used at least one treatment of antibiotics
during the follow-up time. We divided the antibi-
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TABLE 2. Differences between the relapse group and the women free of disease according to the results in
the questionnaire
Free of disease (n 21) Relapse group (n 23)
% No. % No. P Missing data
IUD use 19 (4) 30 (7) NS
Hormonal contraception 29 (6) 26 (6) NS
Candida infection 43 (9) 52 (I 2) NS
Broad-spectrum antibiotics 47 (8/I 7) 53 (7/I 3) NS
Cured at first treatment 95 (19/20) 72 (16/22) NS
Bleeding disturbances 19 (4) 35 (8) NS
CIN 24 (5) 17 (4) NS
Major gynecological surgery 35 (8) 30 (7) NS
Hysterectomy 24 (5) 13 (3) NS
Pregnancy 9 (2) 18 (4) NS
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43 patients with 56 month follow up
31 patients with 72 month follow up
Second relapse 15 patients with 56 month follow up
Survival analysis based on number of months the women were followed from the initial cure.
otics into simple and broad-spectrum antibiotics.
When the patient did not remember the antibiotic,
we chose to classify her in the broad-spectrum anti-
biotic group if treatment was given for infection other
than urinary tract infection or upper respiratory
tract infection. This is not a very precise definition,
but the use of simple or broad-spectrum antibiotics
did not influence the recurrence rate of BV.
An association has been reported between intra-
uterine device (IUD) users and BV. 9,13 In our
study, IUD use was not associated with relapse of
BV, but only 11 women used an IUD.
A long-term follow-up study could show an in-
creased rate of hysterectomies among women with
relapse of BV if bleeding disturbances are related
tO BV. 14,15 We found no correlation between re-
lapse of BV and bleeding disturbances or hysterec-
tomies. However, we found a very high overall gy-
necological morbidity among the 44 women stud-
ied. Fifteen women had had major gynecological
operations during the study period, i.e., inconti-
nence (1), laparoscopy (3), hysterectomy (8), and
adnexal-tubal operations (3). Four women had had
other surgery.
Relapse of BV was not related to the develop-
ment of CIN, but a high overall incidence of CIN
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was present. Nine of the 44 women had CIN di-
agnosed during the study period, including 3
women with severe CIN or cancer in situ (CIS).
This could be a coincidence, a selection bias, or a
result of an existing correlation between BV and
CIN. 1-6 Our results suggest that a woman who has
ever had BV might be at risk of developing CIN
and may even be recommended for regular screen-
ing for cytological atypia.
The main weakness of this study is that we have
not examined the women on a scheduled basis ev-
ery year. We therefore do not know if all episodes
of BV have come to our attention. However, our
population has been rather stable in time and
place, which is why it has been possible to inves-
tigate most of the women at our outpatient clinic
on a regular basis. This study was initiated 5 years
after the initial treatment study. Although we had
no intention of a follow-up study, most J3f the pa-
tients (33 women) were still visiting our clinic and
the follow-up study was easy to perform. The 4
women with self-taken smears had moved .to an-
other region in the country a couple of years after
the initial treatment study, and our only knowledge
of these women came from the questionnaire and
the self-taken smear. Three of the 4 women had a
typical BV flora on the wet smear at 6 years follow-
up and were in the relapse group. The exact time
for the relapse is uncertain but is calculated as the
day of the diagnosis. As the women with self-taken
smears were not diagnosed according to the criteria
of Amsel et al.9 but solely by microscopy, we dis-
cussed the possibility of excluding them from fur-
ther analysis. However, we have shown that diag-
nosing BV with rehydrated air-dried smears is a
reliable alternative to the criteria of Amsel et al.
(Kappa index 0.93 comparing the two meth-
ods). 11 An exclusion of these women would lead to
a lower relapse rate of BV.
Among pregnant women BV can shift spontane-
ously to a normal vaginal flora, 17 but this has not
been shown for non-pregnant women. If BV is a
self-curable disease we would expect the cure rate
after placebo treatment to be much higher than the
5-10% cure rates reported after oral placebo,z Only
one longitudinal follow-up study of untreated BV
in non-pregnant women has been published, in
which about 30% of the women with BV were
cured spontaneously over a 6 month period.
8
However, the diagnosis of BV was not according to
the established diagnosing methods for BV, but
"vaginal discharge was defined as abnormal and
considered suggestive of BV if it was negative for
trichomonads and yeast and had one of the follow-
ing characteristics: 1) excessive volume, 2) abnor-
mal consistency, or 3) characteristic fishy odor. ’’8
The persistence of BV according to this definition
is difficult to compare to established criteria.9
The HzOz production by lactobacilli may act as
an antimicrobial defense system in the vagina. Es-
chenbach et al.z found a low HzOz production of
lactobacilli from women with BV and Hawes et
al.9 found that HzOe-producing lactobacilli pre-
vented the acquisition of BV. We cultured all
women with lactobacillus flora on wet smear at the
6 years follow-up visit. We were only able to isolate
lactobacilli (from Rogosa and blood agar cultured
anaerobically) in half of the women, although the
wet smears had lactobacillus morphotypes. This
could be due to transportation difficulties as the
vaginal samples were transported by mail using
Stuart’s transport medium with transportation time
of 1-3 days. We did not find any correlation be-
tween the HzOz production of the lactobacilli and
relapes of BV and we only isolated very few lacto-
bacilli. However, the lactobacilli cultured may not
have been the predominating species visible in the
wet smear, and our cultures were often performed
months or years after the BV recovery.
Survival analysis of the 43 patients with a follow-
up time of 56 months shows that most of the re-
lapses occurred during the first year after treat-
ment. In the survival analysis based on 72 months
observation two very late relapses occurred. For
these two women, we feel quite sure that the re-
lapse is as late as indicated, as both reported that
they just developed symptoms of BV and planned
to call us for an appointment when the follow-up
visit was offered. Survival analysis of 15 women
with a second relapse also shows that the second
relapse occurred within the first 2 years after treat-
ment, but this observation is not as distinct as for
the first relapse.
Data from both Gardnerz and Amsel et al.9 sug-
gest a sexual transmission of BV. Gardnerz inocu-
lated pregnant women with vaginal fluid from
women with BV and showed that the inoculated
women got BV. In a survey from a health screening
program for cytological atypia we found that
women with BV significantly more often had had
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new sexual contacts than women without BV. zl
Hawes et al. 19 reported that the risk of acquiring
BV doubled during a 2 year follow-up period if the
women had had a new sexual partner. Among mo-
nogamous lesbians, BV occurred in both partners
20 times more often if one of the women had BV,
suggesting a sexual transmission between lesbi-
ans.zz Our data also support the theory of sexual
transmission for BV as a new sexual contact was
related to relapses. However, we do not know if the
new sexual contact occurred in relation to the re-
lapse. The early relapses may have another etiol-
ogy than the late relapses where a new infection
from a contagious relation may play a role.
On the basis of this study, the relapse rate after
successful treatment of BV appears relatively low,
especially after the first year, and we recommend
treatment of asymptomatic as well as symptomatic
women with BV, and stress the importance of care-
ful follow-up.
REFERENCES
1. Pheifer TA, Forsyth PS, Durfee MA, Pollock HM,
Holmes KK: Nonspecific vaginitis: role of Haemophilus
vaginalis and treatment of metronidazole. N Engl J Med
298:1429-1434, 1978.
2. Larsson PG: Treatment of bacterial vaginosis (editorial).
Int J STD AIDS 3:239-247, 1992.
3. Sobel JD, Schmitt C, Meriwether C: Long-term follow-
up of patients with bacterial vaginosis treated with oral
metronidazole and topical clindamycin (letter). J Infect
Dis 167:783-784, 1993.
4. Larsson PG, Bergman B, Forsum U, Phlson C: Treat-
ment of bacterial vaginosis in women with vaginal
bleeding complications or discharge and harboring Mo-
biluncus. Gynecol Obstet Invest 29:296-300, 1990.
5. Hart G: Risk profiles and epidemiologic interrelation-
ships of sexually transmitted diseases. Sex Transm Dis
20:126-136, 1993.
6. Joesoef MR, Wiknjosastro G, Norojono W, et al.: Coin-
fection with chlamydia and gonorrhoea among pregnant
women and bacterial vaginosis. Int J STD AIDS 7:61-
64, 1996.
7. Eschenbach DA, Hillier S, Critchlow C, et al.: Diagnosis
and clinical manifestations of bacterial vaginosis. Am J
Obstet Gynecol 158:819-828, 1988.
8. Thomason JL, Gelbart SM, Anderson RJ, et al.: Statis-
tical evaluation of diagnostic criteria for bacterial vagi-
nosis. Am J Obstet Gynecol 162:155-160, 1990.
9. Amsel R, Totten PA, Spiegel CA, et al.: Nonspecific
vaginitis. Diagnostic criteria and microbial and epide-
miologic associations. Am Med 74:14-22, 1983.
10. Morgan DJ, Aboud CJ, McCaffrey IM, et al.: Compari-
son of Gram-stained smears prepared from blind vaginal
swabs with those obtained at speculum examination for
the assessment of vaginal flora. Br J Obstet Gynaecol
103:1105-1108, 1996.
11. Larsson PG, Platz-Christensen JJ: Enumeration of clue
cells in rehydrated air-dried vaginal wet smears for the
diagnosis of bacterial vaginosis. Obstet Gynecol 6:727-
730, 1990.
12. Eschenbach DA, Davick PR, Williams BL, et al.: Preva-
lence of hydrogen peroxide-producing Lactobacillus spe-
cies in normal women and women with bacterial vagi-
nosis. J Clin Microbiol 27:251-256, 1989.
13. Moi H: Prevalence of bacterial vaginosis and its associa-
tion with genital infections, inflammation and contra-
ceptive methods in women attending sexually transmit-
ted disease and primary health clinics. Int J STD AIDS
1:86-94, 1990.
14. Larsson PG, Bergman BB: Is there a causal connection
between motile curved rods, Mobiluncus species, and
bleeding complications? Am J Obstet Gynecol 154:107-
108, 1986.
15. Nygaard OG, Csing6 PA, Jagars G: Treatment in gen-
eral practice of bacterial vaginosis associated with Mobi-
luncus species (English abstract). Tidsskr Nor Lege-
foren 111:845-847, 1991.
16. Platz-Christensen JJ, Sundstrom E, Larsson PG: Bacte-
rial vaginosis and cervical intraepithelial neoplasia. Acta
Obstet Gynecol Scand 73:586-588, 1994.
17. Platz-Christensen JJ, Pernevi P, Hagmar B, et al.: A
longitudinal follow-up of bacterial vaginosis during
pregnancy. Acta Obstet Gynecol Scand 72:99-102, 1993.
18. Bump RC, Zuspan FP, Buesching IW, Ayers LW, Ste-
phens TJ: The prevalence, six-month persistence, and
predictive values of laboratory indicators of bacterial
vaginosis (nonspecific vaginitis) in asymptomatic
women. Am J Obstet Gynecol 150:917-924, 1984.
19. Hawes SE, Hillier SL, Benedetti J, et al.: Hydrogen
peroxide-producing lactobacilli and acquisition of vagi-
nal infections. J Infect Dis 174:1058-1063, 1996.
20. Gardner HL: Haemophilus vaginalis vaginitis after
twenty-five years. Am J Obstet Gynecol 137:385-390,
1980.
21. Larsson PG, Platz-Christensen JJ, Sundstrtim E: Is bac-
terial vaginosis a sexually transmitted disease? Int J
STD AIDS 2:362-364, 1991.
22. Berger BJ, Kolton S, Zenilman JM, et al.: Bacterial vag-
inosis in lesbians: A sexually transmitted disease. Clin
Infect Dis 21:1402-1405, 1995.
302 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY